Loncar Investments has partnered up with Exchange Traded Concepts to launch a new ETF that tracks the growing biopharmaceutical sector in China.
On Wednesday, Loncar Investments rolled out the Loncar China BioPharma ETF (NasdaqGM: CHNA), which has a 0.79% expense ratio.
“China aims to become a leader in global medicine,” Brad Loncar, Chief Executive Officer of Loncar Investments, said in a note. “Regulatory reform and a new rule allowing pre-revenue biotech companies to list on the Hong Kong Stock Exchange may signal a new era for innovative drug development in the region. We think this is an important trend in healthcare, as it has the potential to spur growth and benefit patients worldwide.”
The China Food and Drug Administration has enacted recent reforms as the country modernizes the industry. Meanwhile, more Chinese citizens are able to afford innovative medicines as their standard of living rises.
The Loncar China BioPharma ETF tries to reflect the performance of the Loncar China BioPharma Index, which tracks 22 Hong Kong-listed and six Nasdaq-listed pharmaceutical and biotech related Chinese companies. The underlying index includes pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers or distributors of biopharma products, and biopharma service providers, according to the fund’s prospectus.